Modulation of PTPIP51 with LCD3/Dynarrestin could modify related signaling pathways in AD and create a “cascade-like” Ca2+ homeostasis, due to its potential in modulating the ER to mitochondria apposition. Here, RMDN3 is linked to Alzheimer disease.